All-Oral Treatment Combo for AML Earns FDA Nod

Published Date: 15 May 2026

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Read Full News

Latest News

Annual Cancer Report Highlights Advances, Funding Threats

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

Does Telenursing Improve QOL in Breast Cancer?

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

Long-Term Results Favor Acalabrutinib Combo in MCL

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

First-Line Combo Therapies Best Chemo Alone in NSCLC Trials

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

3D Mammography Improves Long-Term Cancer Risk Prediction

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Osimertinib's OS Benefit in Resected NSCLC Persists 8 Years

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

Todays Updates

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

FDA News Recap: Novel Drug Approvals in Q2 2026

FDA News Recap: Novel Drug Approvals in Q2 2026

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

7 Pulmonology Headlines You Missed in August 2026 Victoria Johnson

August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.

Lung Cancer Diagnosis Linked to Lung Microplastic Presence, Quantity Victoria Johnson

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Todays Updates

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

Spotlighting Updates in Psoriasis, PsA Management in 2026, With Philip Mease, MD

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

Nipocalimab Reduces Disease Activity in Moderate-to-Severe SLE in Phase 2 Trial

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

FDA Approves Risankizumab for Pediatric Plaque Psoriasis, Psoriatic Arthritis

FDA News Recap: Novel Drug Approvals in Q2 2026

FDA News Recap: Novel Drug Approvals in Q2 2026

Pulmonary NPs Debate Biologic Escalation in Asthma, COPD Care Victoria Johnson

Nurse practitioners discuss escalating biologic therapy for asthma and COPD, mucus plugging data, and access barriers.

7 Pulmonology Headlines You Missed in August 2026 Victoria Johnson

August 2026 pulmonology highlights include deupirfenidone's positive phase 2b ELEVATE-IPF results, FDA Fast Track for LTI-03, and more.

Lung Cancer Diagnosis Linked to Lung Microplastic Presence, Quantity Victoria Johnson

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Latest News

A yearly report from the American Association for Cancer Research lauds recent breakthroughs but warns on threatened federal funding changes.

A meta-analysis assesses the effect of nurse-led telenursing on the quality of life in women with breast cancer.

The 50-month follow-up of the ECHO trial underscores greater benefits with concurrent vs sequential addition of acalabrutinib to bendamustine and rituximab.

New phase 3 data add to a growing number of EGFR-directed first-line options for advanced NSCLC with EGFR exon 20 insertions.

Researchers develop and validate a deep learning model using longitudinal 3D tomosynthesis examinations to predict individualized 5-year risk for breast cancer.

Even years after treatment ends, adjuvant osimertinib brings an overall survival benefit to patients with resected EGFR-mutated lung cancer.

News All Time

Tissue-Free ctDNA Predicts Recurrence in Early Breast Cancer

Researchers analyzed plasma samples collected from 313 patients with early breast cancer approximately 2 years after they had completed adjuvant chemotherapy.

SBRT Plus Atezolizumab Shows No Benefit in Inoperable NSCLC

For patients with early-stage, inoperable lung cancer, adding atezolizumab to standard radiotherapy boosts toxicity, not survival.

TKI Discontinuation Feasible After ALL Treatment

In patients with first- or second-line Philadelphia-positive B-cell acute lymphoblastic leukemia, favorable outcomes are observed with discontinuation of ponatinib.

Sevabertinib Approved for First-Line Mutated NSCLC

The oral HER2 TKI was previously given accelerated approval in the second line for the indication.

A New PARADIGM? Azacitidine-Venetoclax Tops Chemo in AML

The less-intensive drug combination outperforms standard induction chemotherapy in fit patients with acute myeloid leukemia.

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Long-Acting Interferon Therapy Approved for ET

Ropeginterferon alfa-2b is designed to provide durable disease control.

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

FDA Approves Rusfertide for Polycythemia Vera

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Recommended News For You

Liquid Biopsy for Colorectal Cancer Screening Might Not Be Ready for Prime Time.

Experts say oncology, primary care coordination necessary for best cancer patient outcomes

SBRT Misses the Mark in Prostate Cancer Trial

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

Trial Challenges Indefinite Maintenance for Multiple Myeloma

Firefighters who eat better can combat cancer.

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

Recommended Articles For You

Pathophysiology of Cellular Iron Redistribution During Chronic Inflammation 

Understanding the HAS-BLED Score: What It Is and Why It Matters  

Clinical Pharmacology of Tumor Microenvironment-Activated Prodrugs 

Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Which Salvage Therapy Is Best for Recurrent Prostate Cancer?

2.

All-Oral Treatment Combo for AML Earns FDA Nod

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

A large study found that monolayers were superior in detecting cancer.

5.

Can the way we talk about cancer change how we interact with the disease?

1.

Precision Oncology: Cancer Screening, Genetic Counseling & Hereditary Cancer Syndromes Integration

2.

Mechanisms of Lactylation-Driven Metabolic Reprogramming in Cancer

3.

Molecular Matching for Complex Blood Disorders

4.

Don't Ignore Your Vision Loss: What You Need to Know About Amaurosis Fugax 

5.

Prevention Through Preservation of Hematopoietic Reserve During Chronic Physiological Stress

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Newer Immunotherapies for Myeloma- A Comprehensive Overview

2.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment

3.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I

5.

Managing CNS diseases at the point of diagnosis in ALK + NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot